A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting

References

• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–881.
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre (UK). Psoriasis: assessment and management of psoriasis. NICE Clinical Guidelines. No. 153. London: Royal College of Physicians (UK); 2012.
   Google Scholar
• Abdulrahim H, Thistleton S, Adebajo AO, et al. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16(7):1099–1108.
   PubMed Web of Science ®Google Scholar
• Otezla. Summary of Product Characteristics [Internet]. [cited 2019 May 8]. Available from: https://ec.europa.eu/health/documents/community-register/2015/20150115130395/anx_130395_en.pdf.
   Google Scholar
• Bewley A, Barker J, Mughal F, et al. Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. Cogent Med. 2018;5(1):1495593..
   Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1–233.
   PubMed Web of Science ®Google Scholar
• National Clinical Guidelines Centre. Appendix P – Review of resource use and cost data to use in defining ‘best supportive care’ for NCGC economic model [Internet]. [cited 2019 May 8]. Available from: https://www.nice.org.uk/guidance/cg153/evidence/appendices-ju-pdf-188351538.
   Google Scholar
• Iskandar IY, Ashcroft DM, Warren RB, et al. Patterns of biologic therapy use in the management of psoriasis: Cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2017;176(5):1297–1307.
   PubMed Web of Science ®Google Scholar
• Mughal F, Cawston H, Kinah D, et al. Cost effectiveness of Apremilast in moderate to severe psoriasis in Scotland. ISPOR 18th Annual European Congress. 2015. Nov 7–11; MiCo - Milano Congressi, Milan, Italy.
   Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety result from the randomised controlled comparative study of adalimumab vs. metotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2007;158(3):558–566.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022.
   PubMed Web of Science ®Google Scholar
• Turner D, Picot J, Cooper K, et al. Adalimumab for the treatment of psoriasis. Health Technol Assess. 2009;13 (Suppl 2):49–54.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216(3):260–270.
   PubMed Web of Science ®Google Scholar
• DETERMINAZIONE AIFA 3 luglio 2006. Elenco dei medicinali di classe a) rimborsabili dal Servizio sanitario nazionale (SSN) ai sensi dell’articolo 48, comma 5, lettera c), del decreto-legge 30 settembre 2003, n. 269, convertito, con modificazioni, nella legge 24 novembre 2006, n. 326. (Prontuario farmaceutico nazionale 2006). (Gazzetta Ufficiale Serie Generale n.156 del 07-07-2006 - Suppl. Ordinario n. 161)
   Google Scholar
• DETERMINAZIONE AIFA 27 settembre 2006. Manovra per il governo della spesa farmaceutica convenzionata e non convenzionata. (Gazzetta Ufficiale Serie Generale n.227 del 29-09-2006)
   Google Scholar
• Ministero della Salute. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Gazzetta Ufficiale – Serie Generale n. 23 del 28-01-2013. Suppl. Ordinario n. 8.
   Google Scholar
• Mease PJ. Apremilast: A phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther. 2014;1(1):1–20.
   PubMedGoogle Scholar
• Associazione Italiana di Economia Sanitaria. Proposta di linee guida per la valutazione economica degli interventi sanitari. Politiche Sanitarie. 2009;10(2):91–99.
   Google Scholar
• Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venerol. 2008;22(3):324–329.
   PubMed Web of Science ®Google Scholar
• Istituto Nazionale di Statistica [Internet]. Available from: www.istat.it.
   Google Scholar
• Kheraoui F, Favaretti C, Ferriero AM, et al. Apremilast nel trattamento della psoriasi e dell’artrite psoriasica: risultati di una valutazione di Health Technology Assessment. QIJPH. 2017;6(2):1–116.
   Google Scholar
• Degli Esposti L, Perrone V, Sangiorgi D, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. BTT. 2018;12:151–158.
   Google Scholar
• Nash P, Ohson K, Walsh J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018;77(5):690–698.
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507–517.
   PubMed Web of Science ®Google Scholar
• Papadavid E, Rompoti N, Theodoropoulos K, et al. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;32(7):1173–1179.
   PubMed Web of Science ®Google Scholar
• Mughal F, Barker J, Cawston H, et al. Cost-effectiveness of apremilast in moderate to severe psoriasis in the UK. J Am Acad Dermatol. 2016;74(5):AB243.
   Google Scholar
• Carrascosa JM, Vanaclocha F, Caloto T, et al. Cost-utility analysis of apremilast for the treatment of moderate to severe psoriasis. Value Health. 2015;18(7):A420.
   Web of Science ®Google Scholar
• Mughal F, Cawston H, Kinahan D, et al. Cost-effectiveness of apremilast in moderate to severe psoriasis in the Scotland. Value Health. 2015;18(7):A420.
   Web of Science ®Google Scholar
• Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13(7):848–853.
   PubMed Web of Science ®Google Scholar